Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant pembrolizumab feasibility study in dMMR/POLE-mutated uterine cancer
NL-OMON49601Phase 2Active, not recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Dec 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab in uterine cancer and endometrial cancer (EC), sponsored by University Medical Center Groningen. Primary endpoint: Pathological response. Started Dec 2020; status: active, not recruiting.
02
Drugs
03
Conditions
uterine cancerendometrial cancer (EC)
Beyond the preview
Go deeper on NL-OMON49601.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON49601.